Research Article
Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B
Table 2
Comparison of clinical and histological characteristics between ETV monotherapy resistant and effective hepatitis B patients.
| | Characteristics | Resistant group (n = 15) | Effective group (n = 97) | value |
| | Age at the beginning (years (median, IQR)) | 48.0 (37.0–61.0) | 63.0 (54.5–71.0) | | | Gender (M/F (n, %)) | 12 (80.0)/3 (20.0) | 48 (49.5)/49 (50.5) | | | Baseline AST (U/L (median, IQR)) | 65.0 (25.0–83.0) | 35.0 (23.0–64.5) | n. s. | | Baseline ALT (U/L (median, IQR)) | 95.0 (34.0–161.0) | 36.0 (21.0–74.8) | | | Prior NA exposure (yes/no (n, %)) | 3 (20.0)/12 (80.0) | 18 (18.6)/79 (81.4) | n. s. | | Baseline HBeAg (+/−/unknown (n, %)) | 10 (66.7)/5 (33.3)/0 (0.0) | 31 (32.0)/52 (53.6)/14 (14.4) | | | Baseline HBV DNA (LogC/mL (median, IQR)) | 7.6 (5.4–8.9) | 4.4 (2.3–7.0) | | | Baseline HBcrAg (LogU/mL (median, IQR)) | 6.8 (5.9–6.8) | 4.1 (3.0–6.8) | | | Genotype (A/B/C/D/unknown (n, %)) | 0 (0.0)/3 (20.0)/12 (80.0)/0 (0.0)/0 (0.0) | 3 (3.5)/10 (9.6)/50 (50.4)/1 (0.9)/33(40.0) | n. s. | | Fibrosis stage (F1/F2/F3/F4/unknown (n, %)) | 3 (20.0)/7 (46.7)/1 (6.7)/1 (6.7)/3 (20.0) | 4 (4.1)/19 (19.6)/9 (9.3)/3 (3.1)/62 (63.9) | n. s. |
|
|
